news

Sytheon Raises the Limit of Isosorbide Esters to the Max

– From Skin Care to Brain Care

Sytheon researchers published a paper – “A novel fumarate, isosorbide di-(methyl fumarate) (IDMF), replicates astrocytes transcriptome responses to dimethyl fumarate (DMF) but specifically down-regulates genes linked to a reactive phenotype” in Biochemical & Biophysical Research Communication, https://doi.org/10.1016/j.bbrc.2020.08.079.

Dimethyl fumarate (DMF), trade named Tecfidera with over $4B annual sales, is marketed by Biogen as a first-line therapy for the relapse-remitting multiple sclerosis (RRMS) subtype. DMF treatment, however, is limited in some RRMS patients due to adverse effects (e.g., gastrointestinal symptoms, flushing, and lymphopenia). This has increased focus on the development of new fumarates that may have similar efficacy to DMF but will be more tolerable for RRMS patients. Sytheon focused on RNA-seq to characterize transcriptional responses to DMF in cultured astrocytes. Effects of DMF were then compared to those of isosorbide di-(methyl fumarate) (IDMF), which is a novel fumarate not previously evaluated as an RRMS treatment.

Our findings show that both DMF and IDMF alter the expression of MS-associated genes involved in antioxidant defense (HMOX1), extracellular matrix (MMP9, TIMP3), and inflammatory cell chemotaxis (CCL2). However, IDMF had specific effects downregulating the expression of genes linked to the cell cycle and a reactive astrocyte phenotype (ICAM1). These findings provide the first study of genome-wide expression responses to DMF in astrocytes and thus help to define astrocyte-centered mechanisms that may contribute to the efficacy of DMF as an RRMS treatment.

In addition, our results show that IDMF partially replicates transcriptional effects of DMF but also uniquely suppresses a gene circuit linked to the cell cycle and proliferation. Our findings, therefore, support a rationale for further evaluation of IDMF as a novel RRMS treatment with enhanced potential for activity against reactive gliosis and MS lesion scar formation with better tolerability.

Defining the mechanism of IDMF, demonstrating its potential superiority over DMF, and having secured broad patent coverage, Sytheon stakes claim through its sister company, Symbionyx Pharmaceu­ticals Inc., to delve into relapse-remitting multiple sclerosis market through partnership.

For more information, please contact: info@sytheonltd.com

Sytheon’s CEO to Speak at NYSCC Acne Care Symposium

Sytheon’s CEO to Speak at NYSCC Acne Care Symposium

Ratan K. Chaudhuri, Ph.D., President and CEO at Sytheon, will discuss key strategic targets for mitigating acne-affected skin. Sytheon, a...

by Drew FrantzenMay 19, 2023
Read More
Sytheon is excited to announce a publication on Synergistic…

Sytheon is excited to announce a publication on Synergistic…

Sytheon is excited to announce a publication on Synergistic Anti-Inflammatory Effects of Isosorbide Fatty Acid Diesters in Cytokine-Induced Tissue Culture...

by hostingagencyusDecember 6, 2022
Read More
Founder and CEO Dr. Ratan Chaudhuri has been named as a top 10…

Founder and CEO Dr. Ratan Chaudhuri has been named as a top 10…

Founder and CEO Dr. Ratan Chaudhuri has been named as a top 10 inspiring business leader by Inc. magazine to...

by hostingagencyusOctober 6, 2022
Read More
Sytenol® A is Accepted for Use in the Chinese Market

Sytenol® A is Accepted for Use in the Chinese Market

We are pleased to announce that Sytenol® A (Bakuchiol) has been successfully notified as a medium-low risk new cosmetic ingredient...

by hostingagencyusAugust 31, 2022
Read More
Sytheon Announces Relocation and Expansion of New Corporate Headquarters

Sytheon Announces Relocation and Expansion of New Corporate Headquarters

Sytheon relocates its headquarters to 10 Waterview Blvd, Parsippany, NJ. The move to a new state-of-the-art facility stems from Sytheon’s...

by hostingagencyusAugust 1, 2022
Read More
Bakuchiol – A natural alternative to Retinol shows holistic treatment approach…

Bakuchiol – A natural alternative to Retinol shows holistic treatment approach…

Bakuchiol – A natural alternative to Retinol shows holistic treatment approach for facial aging based on its multidirectional activity Beiersdorf...

by hostingagencyusJune 3, 2022
Read More